Skip to content
Screener

Climb Bio, Inc. CLYM Price / book

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.3×-0.2×
Amgen logo
AmgenAMGN
16.7×-3.4×
Vera Therapeutics logo
Vera TherapeuticsVERA
5.7×+2.9×
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
2.7×+2.3×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
1.5×+0.3×
Jade Biosciences logo
Jade BiosciencesJBIO
2.3×—

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K—
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$804.11M+621%
Enterprise value$796.23M+790%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0×0.0×
Current ratio27.9×+13.6×

Where this comes from

Calculated from Climb Bio, Inc.’s reported figures.

market cap/total stockholders equity=2.2×

Based on the most recent quarter.

The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 7:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210357

FAQ

What is Climb Bio, Inc.'s price / book?
Climb Bio, Inc. (CLYM) reported price / book of 2.2× in Q1 2026.
How has Climb Bio, Inc.'s price / book changed year-over-year?
Climb Bio, Inc.'s price / book increased by 419.1% year-over-year, from 0.4× to 2.2×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Climb Bio, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude